Background: Studies on the effect of inadequate empirical antibiotic therapy on the outcome of patients with systemic infection have led to inconsistent results.
Introduction
Bloodstream infection (BSI) continues to be a severe and often life-threatening condition. 1 -3 Antibiotics are generally thought of as a cornerstone for the treatment of BSIs. A delay in adequate antibiotic therapy may lead to progressive deterioration and the development of complications. 4 Major guidelines in treating serious bacterial infections advocate the early administration of empirical broad-spectrum antibiotics before the results of blood culture and drug susceptibility tests are available. 5 Clinical studies on the benefit of adequate antibiotic therapy, however, have shown inconsistent findings. Some studies demonstrated a negative impact of inadequate empirical antibiotic therapy, 6 -13 whereas others did not find an increase in mortality attributable to inadequate empirical antibiotic therapy. 14 -17 One of the major problems in analysing the impact of inadequate antibiotic therapy on the outcome is the confounding by indication for the choice of antibiotic treatment. Patients do not receive adequate or inadequate empirical antibiotic therapy at random. Rather, the adequacy of the initial antibiotic therapy is greatly influenced by the physician's initial medical judgement on the risk of resistant strains. It has been shown that patients receiving inadequate empirical antibiotic therapy are likely to be those at risk for carrying resistant strains, as seen in nursing home residents, indwelling catheter carriers or those with recent exposure to healthcare facilities. 6 -17 Another concern is confounding by severity. In the emergency department (ED) setting, the source of bacteria may not be clear in the first few hours of the workup, and the empirical use of antibiotics may be dependent on a physician's medical judgement on the clinical severity of disease and source of infection.
Randomized controlled trials are the best solution to clarify the sources of confounding, but they may not be feasible due to ethical considerations. Traditional methods used to correct confounding include matching the predictors associated with inadequate antibiotic therapy or building a multivariable regression model that includes all potential confounders. However, when there are numerous potential risk factors, such analytic strategies may fail due to the sparse data in each matched stratum. Propensity score (PS) analysis can address this problem by collapsing the predictors of inadequate antibiotic therapy into a single value by a multivariable scoring system. 18 In this study we use PS analysis to evaluate the impact of adequate empirical antimicrobial therapy on 30 day all-cause mortality rates and the length of stay.
Patients and methods
The study cohort was a community-based comprehensive bacteraemia database prospectively collected in the ED of a university hospital from June 2008 to June 2009. The university hospital is a 2400 bed primary and tertiary care hospital with an annual ED case load of more than 100000 visits. This study was reviewed and approved by the Institutional Review Board. During the study period, patients who fulfilled the criteria of sepsis or showed a clinical picture of severe infectious disease and evident infectious foci were prescribed two sets of blood cultures. Patients with clinically significant positive blood culture results were then prospectively enrolled. Demographic and clinical data in the ED were recorded by a standardized form. All patients received standard supportive treatment including surgical treatment of the focus, fluid resuscitation, or vasopressive agents when necessary. Empirical antimicrobial therapy was chosen by the primary physician and administered until the point at which culture and antibiotic susceptibility test results were known.
Definitions
An episode of BSI was considered to be community-onset if it developed in a patient prior to the hospital or intensive care unit (ICU) admission. Operationally, we excluded from our study those patients with a history of hospitalization within 48 h of the ED visit. True BSI was defined as at least two sets of positive blood cultures at separate sites or one set for Gram-negative bacterial pathogens or for Gram-positive pathogens in patients with an intravascular device and a clinical picture consistent with BSI. Coagulase-negative staphylococci and other common skin flora isolated in single blood cultures without clinical risk and compatible disease course were viewed as contamination. Fungaemia was not included in this study.
Therapy was considered adequate when at least one intravenous antimicrobial was given within 24 h of ED admission, and the dose and pattern of administration must be in accordance with current medical standards. The adequacy of the antibiotic is determined by in vitro susceptibility of the specific bacteria isolate. In the case of polymicrobial infections, the adequacy of the antibiotic was determined by in vitro susceptibility for all isolates. For lower respiratory tract infection, common empirical antibiotic regimens in our institution included b-lactamase inhibitorpotentiated aminopenicillin plus macrolide or quinolone alone; for urinary tract infection, first-generation cephalosporin with or without aminoglycoside; for biliary tract infection or intra-abdominal infection, secondor third-generation cephalosporin with anti-anaerobe agents; for musculoskeletal infection, oxacillin; and for catheter-related infection or infective endocarditis, oxacillin or vancomycin. The prevalence of antibiotic resistance for major pathogens in this sample is as follows: 28.7% of Staphylococcus aureus resistant to methicillin, 60% of Streptococcus pneumoniae resistant to penicillin, 8.8% of Escherichia coli resistant to quinolone, and 4.2% of Klebsiella pneumoniae resistant to quinolone.
The source of infection was classified as one of the following: lower respiratory tract, intra-abdominal, urinary tract, biliary tract, skin and musculoskeletal, central nervous system, liver abscess, spontaneous bacterial peritonitis, infective endocarditis, catheter-related infection, or primary bacteraemia with unknown focus. Endocarditis was documented on the basis of clinical, echocardiographic, or pathological evidence. The Charlson comorbidity scoring system was used to assess previous underlying chronic diseases. All patients were followed-up until discharge or death. The 30 day all-cause mortality rate was used as the primary outcome. The 30 day survival status was confirmed by either hospital records or telephone interviews for all enrolled patients.
For the grading of disease severity, the newly developed and validated Mortality in Emergency Department Sepsis (MEDS) scoring system was designed for ED patients. 19, 20 The MEDS score is calculated as the sum of the assigned points of the nine clinical variables: terminal illness (6 points), tachypnoea or hypoxia (3 points), septic shock (3 points), thrombocytopenia (3 points), bandaemia (3 points), age .65 years (3 points), lower respiratory tract infection (3 points), nursing home resident status (2 points) and altered mental status (2 points). The definitions of the symptoms and signs were in accordance with the original work of Shapiro et al.
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In addition, we use the sepsis classification system to define the severity of the disease. 22 Systemic inflammatory response syndrome (SIRS) is defined as the presence of two or more of the following: (i) tachycardia; (ii) tachypnoea or hypoxia; (iii) hyperthermia or hypothermia; or (iv) leucocytosis, leucopenia or bandaemia. 23 Severe sepsis is defined as two or more criteria for SIRS plus organ dysfunction (altered mental status, oxygen saturation ,90%, acute renal failure or abnormal liver enzymes in the absence of explainable liver disease). Septic shock is defined as severe sepsis plus hypotension. We also listed an additional category in this system, uncomplicated bacteraemia, for those who did not meet any of the three sepsis classifications.
Statistical analysis
The potential risk factors for inadequate empirical antibiotic therapy were first examined by means of univariate analysis. All data were assumed to have non-normal distribution. The comparison between the groups was performed using Fisher's exact test as indicated for categorical variables and non-parametric Mann-Whitney U-tests for continuous variables.
PS analysis
PS was defined as the conditional probability of having inadequate antibiotic therapy. The score was derived from the logistic model that predicts inadequate empirical antibiotic therapy. The logistic regression model was built by including all potential predictors identified in univariate analysis (P,0.2) and other known risk factors for exposure to a resistant strain, and then backward elimination was used to construct a parsimonious PS model. The predicted probability of each patient derived from this logistic model represents the 'propensity' of each Chen et al. patient to be exposed to inadequate antibiotic therapy. The score was then used to balance the distribution of confounders between the patients with inadequate or adequate empirical antibiotic therapy in Cox model regression analysis. The modified MEDS score was also included in the multivariate Cox model regression analysis to correct the residual confounding due to the confounders not included in the PS. One of the MEDS score variables, nursing home residence, was already included in the PS model. To avoid over-adjustment, we used the modified MEDS score by excluding this variable.
Effect modification
We hypothesized that the impact of inadequate empirical antibiotic therapy on survival may be different in patients with different disease severities. We tested the statistical significance of the product term of inadequate antibiotic therapy and clinical severity classification in the Cox model. We used both the quartile range of the MEDS score and the classification of sepsis severity (uncomplicated bacteraemia, sepsis, severe sepsis and septic shock) for the stratification of clinical severity. Although the MEDS score performs better in the severity stratification, it is not commonly used by physicians other than by emergency medicine specialists. For generalizability and clinical interpretability, we also used the commonly accepted severity classification of sepsis in the analysis. In each severity stratum we showed the differential impact of inadequate antibiotic therapy by different hazard ratios (HRs), risk differences and numbers needed to harm. The number needed to treat in this situation could be interpreted as the number of inadequate antibiotic therapies that need to be avoided to save one life. The HR was obtained by Cox model regression analysis and the risk difference by linear regression analysis in each severity stratum. The number needed to treat was calculated from the inverse of risk difference. A Kaplan-Meier survival curve was plotted to demonstrate the different impacts of inadequate antibiotic therapy on survival for four severity strata. All statistical tests were two-tailed, and P,0.05 was considered to be statistically significant. The data were collected and analysed with STATA 10 (College Station, TX, USA) and SAS 9.13 (SAS Institute, Cary, NC, USA) software.
Results
During the study period, 937 patients with community-onset BSI were included. Of these, 175 (18.7%) patients were then admitted to the ICU and the rest of the patients were admitted to the general ward. Six hundred and twelve (65.3%) patients were infected with Gram-negative pathogens, 241 (25.7%) were infected with Gram-positive pathogens and the remaining 84 were mixed polymicrobial infections. The overall 30 day all-cause mortality rate was 17.0%. A total of 255 (27.2%) patients did not receive adequate empirical antibiotic therapy, and they had a higher 30 day mortality rate than those who received adequate empirical antibiotic therapy (24.3% versus 14.2%, P,0.001).
Patients with inadequate empirical antibiotic therapy were significantly associated with certain underlying characteristics, including a history of recent hospitalization, nursing home exposure, certain sources of infection, and certain bacterial aetiologies. The results of the univariate comparison between patients receiving inadequate or adequate empirical antibiotic therapy are presented in Table 1 .
PS model
The potential risk factors identified in the univariate comparison, age and sex were included in a multivariate logistic regression model. We aimed to test the presence of effect modification by severity classification, so it was not included in the PS model. The final model includes eight positive predictors and two negative predictors ( Table 2 ). The predicted probabilities of inadequate antibiotic therapy from the final model were used as the PSs. The receiver operating characteristic curve analysis showed a c-statistic of 0.73 for the PS model in predicting inadequate antibiotic therapy.
Cox model regression analysis
Univariate Cox model regression analysis showed an increased risk of 1.78 in the 30 day mortality rate due to inadequate antibiotic therapy. The HR decreased with the adjustment for PS and MEDS score in the model. The adjusted analysis showed a 1.77-fold increase in the 30 day mortality rate adjusted for PS and a 1.64-fold increase in the 30 day mortality rate adjusted for both PS and MEDS score (Table 3 ).
Effect modification
The adverse impact of inadequate antibiotic therapy was different in patients with different disease severities (Table 4) . Hypothesis testing showed a significant result for the product term between the clinical disease severity and inadequate antibiotic therapy in the Cox model (P ¼0.009). Stratified by either the quartile MEDS score or the more commonly used severity of sepsis classification, we found that the magnitude of the adverse impact of inadequate antibiotic therapy decreased with increasing clinical disease severity (Table 4) . Although the impact of inadequate antibiotic therapy on the HR scale was greatest in the patients with the least severe disease, the overall mortality rate in the least severe patients was low, and the real number of deaths attributable to inadequate antibiotic therapy may not be as large as that in patients with more severe disease. The actual attributable risk could be better demonstrated by risk difference and number needed to treat, as shown in Table 4 . As shown in Table 4 , we need to avoid 25 episodes of inadequate antibiotic therapies to save one patient with sepsis, whereas we only need to avoid 7 episodes of inadequate antibiotic therapies to save 1 patient with severe sepsis. Kaplan -Meier survival curves also demonstrated that the largest differences in mortality rates related to inadequate antibiotic therapy occurred in patients with moderately severe disease with a MEDS score between 8 and 11 ( Figure 1) .The 30 day mortality rate difference was 15.2% for the MEDS 8 -11 group, larger than it is for the MEDS 0-3 group (0.9%) and the MEDS 4 -7 group (8.6%).
Discussion
The results indicate that inadequate empirical antibiotic therapy is associated with an increased risk for 30 day all-cause mortality in adult patients with community-onset bloodstream infection (HR 1.64, 95% CI 1.19 -2.26), after controlling for important confounders. We also demonstrated that the severity of illness might be an important effect modifier. On the risk-ratio scale, the magnitude of the adverse impact of inadequate antibiotic therapy decreases with elevating disease severity classification. On the risk-difference scale, the absolute impact of inadequate Inadequate empirical antibiotic therapy and mortality in community-onset bloodstream infection 949 JAC antibiotic therapy is greatest in patients with severe sepsis, but less prominent in patients with low or extreme severity. By avoiding inadequate antibiotic therapy in seven patients with severe sepsis, we can potentially save one additional life.
It seemed contradictory that the vast majority of the Gramnegative bacteraemia was found to be a positive predictor of inadequate therapy while Klebsiella pneumoniae and Escherichia coli were negative predictors in our PS model. However, our Chen et al.
data did show that antibiotic-resistant K. pneumoniae and E. coli were far less prevalent than other antibiotic-resistant Gramnegative pathogens, such as Pseudomonas spp., Enterobacter spp., and Salmonella spp. These more prevalent antibioticresistant Gram-negative pathogens are not easily amenable to the common empirical antibiotics regimen. Compared with the previous findings, our results are consistent and corroborative of the hypothesis that the adequacy of initial antibiotics is an important factor for sepsis survival. 6 -12 The reported effect estimates on the OR scale of previous reports were between 1.5 and 2.2, which are compatible with our findings. Despite the similarity of the results, the use of OR as the main effect measure in previous reports may warrant discussion. Using OR as an effect measure in a study with a common outcome may problematically exaggerate the association between the exposure and outcome. The reported short-term mortality for BSI in previous studies ranged from 14.7% to 38.8%, which was not a rare event, therefore the reported magnitude of the association may be questionable. 6 -12,14 -17 In our study we used the HR and risk difference as the main measures of an effect, which we believe provides a more unbiased effect estimate.
Another parameter that makes our findings different from others is the analysis of effect modification. Our results showed that the adverse impact of inadequate antibiotic Inadequate empirical antibiotic therapy and mortality in community-onset bloodstream infection 951 JAC therapy decreased with the advancing severity of illness. In other words, adequate antibiotic therapy may generate greater beneficial effects in patients with less severe disease than with more severe disease. The evolution of an overwhelming sepsis syndrome is a continual pathophysiological process, starting from systemic inflammatory reactions (SIRs), followed by organ dysfunction (severe sepsis), and ending with circulatory collapse (septic shock) or multiple organ failure. It is biologically plausible that adequate antibiotic therapy alone may not reverse the destined mortality in the late stage of sepsis. Therefore our results again support the guideline that adequate antibiotic therapy should be given early in a disease course. 5, 24 Another perspective on the effect modification can be gained from the analysis of risk difference in different severity categories. Although inadequate antibiotic therapy is associated with a greater HR for death in patients with less severe disease, the mortality rate of patients with less severe disease is very low, so the net effect of inadequate antibiotic therapy may not be as large. The risk difference or its inverse, the number needed to treat, can better reflect the absolute clinical effect. As shown in our results, patients with severe sepsis or a MEDS score of 8 -12 are most negatively influenced by inadequate antibiotic therapy. It has been debated whether to advocate the administration of broad-spectrum antibiotics to all patients with signs of sepsis when weighed against the high medical cost of doing so and changes to microbial ecology. 25 Our results may help to find a balance between the arguments on both sides. By defining a smaller target population for which empirical broad-spectrum antibiotic therapy may be most beneficial, we suggest that broad-spectrum antibiotics be used more cautiously on select patients. If broad-spectrum antibiotics are used selectively on patients with severe sepsis or a MEDS score between 8 and 11, it can be reasonably expected that the avoidance of every seven to eight events of inadequate antibiotic therapy may save one additional life in our study population.
Our findings may also help explain why all previous studies have not uniformly observed a significant benefit of adequate antibiotic therapy. In study populations with high disease severity, a relatively small sample size may not have enough power to detect the small difference in mortality between patients with adequate or inadequate antibiotic therapy. In study populations with low disease severity, although the expected HR for inadequate antibiotic therapy is higher, the low death rate may also limit the statistical power to detect differences. There are still other emerging effect modifiers that have not been fully elucidated. Kang et al. 10 found that patients with neutropenia are more susceptible to inadequate antibiotic therapy. Previous reports and our preliminary analysis also indicate that patients infected with Gram-negative bacteria are less affected by the adequacy of antibiotic therapy than patients infected with Grampositive bacteria. 4, 16 Our study attempts to address most of the flaws described by a recent systematic review on the methods to assess the association between adequate antibiotic therapy and survival. 26 Instead of expert consensus, we used in vitro susceptibility test results and the dosing, route and pattern of administration to objectively determine the adequacy of antibiotic therapy. Another major strength of this study is that survival was assessed for the full 30 days, even after discharge. We chose a 30 day rather than long-term mortality rate as the primary end point, which may better fit the plausible window of the biological effects of inadequate antibiotics. It is unlikely initial inadequate antibiotics within 48 h will affect the mortality beyond 30 days. We used different effect measures (HR and risk difference) to describe the different aspects of the clinical effect of inadequate antibiotic therapy. HR describes more about the biological effect, while risk difference (which can be used to calculate the number needed to treat) describes the real impact of inadequate initial empirical antibiotics. The PS method also allowed for a finer adjustment for confounders. We used a standardized severity-of-illness scoring system measured uniformly at the time of ED admission before antibiotic administration to avoid over-adjustment for the intermediate variables that may lead to biased results. Compared with other studies merely focused on in-hospital confounders, our database extends to collect out-of-hospital information. Hospitalization within 90 days of ED admission proved to be an important predictor in our analysis.
For both ethical and practical reasons, the best available study design for this research question is observational. We thus cannot avoid the possible bias inherent with an observational study, such as unmeasured or unobserved confounding factors. In addition, our analysis was limited to patients with microbiologically documented BSIs in whom we could assess the adequacy of antibiotics objectively. However, only 20% -30% patients with clinical sepsis yielded positive blood cultures. Microbiologically documented patients are associated with certain host and pathogen characteristics. We do not know whether the results of this study could apply to patients with systemic infections that are not microbiologically documented. As we have shown in this work, the effect size of inadequate empirical antibiotics may vary with the severity of disease in the studied population; external generalization of the results of this study should take into consideration the severity of the disease in the studied population. It is also noteworthy that the proportionality assumption for the Cox model does not hold in our study. Therefore the effect estimate obtained in our work should be interpreted as a sort of mixed effect averaging across different severity groups. Lastly, we did not collect data on the exact time-to-antibiotics information, which prevented us from performing duration-response analysis. The causal relationship might be strengthened if we could show inadequate empirical therapy had a greater impact on patient outcomes when the duration of the first dose of adequate antibiotics is longer.
To conclude, adequate antibiotic therapy is associated with a survival benefit. The effect of adequate antibiotic therapy is different in patients with different clinical severities. Future studies are required to define more precisely the population that is most likely to benefit from broad-spectrum antibiotic therapy. The information regarding the effect modification by clinical severity should be included in the decision support systems that may ultimately promote not only an effective, but also a cost-effective strategy of empirical antibiotic therapy. 27 
